Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$4.85 USD
+0.29 (6.25%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $4.85 +0.01 (0.10%) 5:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Brokerage Reports
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 61 - 80 ( 90 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Financials; BDTX-189 RP2D Selected; Ph 2 Set to Initiate
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Pushing Forward Through Diversity; Ph 1 Dataset Encouraging
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Shows Improved Safety and Initial Anti-Tumor Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; First Look at BDTX-189 Ahead at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways from 2021 AACR Virtual Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Competitive Landscape Updates from AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
4Q20 Earnings; Preliminary BDTX-189 Data Expected 1H:2021
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Partial Clinical Hold Non-Impactful, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX Presents Preclinical Data for BRAF and FGFR 2/3 MasterKey Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Intriguing Preclinical BRAF and FGFR Programs Could Drive Upside to Our Valuation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biliary Cancer Data Further Supports Tumor Agnostic Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R